19 June 2013
Keywords: cambridge, biotech, sell, retroviral, diagnostic, business, usa
Article | 15 April 1996
Cambridge Biotech of the USA is selling its retroviral diagnostic
business to bioMerieux Vitek, part of bioMerieux of France, for $6.5
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
There are no related articles.
18 June 2013
© 2013 thepharmaletter.com